Retrouver les origines du SARS-CoV-2 dans les phylogénies de coronavirus

Sallard, Erwan; Halloy, José; Casañe, Didier; Decroly, Étienne; Helden, Jacques van

doi:10.1051/medsci/2020123

Cited by 13 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the large-scale vaccination campaigns are expected to tame the COVID-19 pandemic in the coming months, the lack of international coordination/collaboration and the alarmingly rapid emergence of novel strains [ 38 ] are likely to present a significant challenge to these efforts due to the high transmissibility of many novel variants and the reduced vaccine effectiveness against them [ 39 , 40 ]. The vulnerability of the highly specific medicines, such as mAbs, to the SARS-CoV-2 mutations places a premium on the on-going efforts to develop broad-spectrum therapeutics (including both novel and repurposed drugs) that would remain effective not only against the ever-increasing range of SARS-CoV-2 variants, but also the future threats posed by the possible introduction of other coronavidæ to the human population via either zoonotic or lab escape routes [ 41 ]. Native MS has been used as an effective analytical tool in a wide range of drug discovery/development efforts, but it remains disappointingly underutilized in the studies aiming at developing novel therapeutics that target SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor

2021

View full text Add to dashboard Cite

Graphical abstract Native mass spectrometry (MS) enjoyed tremendous success in the past two decades in a wide range of studies aiming at understanding the molecular mechanisms of physiological processes underlying a variety of pathologies and accelerating the drug discovery process. However, the success record of native MS has been surprisingly modest with respect to the most recent challenge facing the biomedical community—the novel coronavirus infection (COVID-19). The major reason for the paucity of successful studies that use native MS to target various aspects of SARS-CoV-2 interaction with its host is the extreme degree of heterogeneity of the viral protein playing a key role in the host cell invasion. Indeed, the SARS-CoV-2 spike protein (S-protein) is extensively glycosylated, presenting a formidable challenge for native MS as a means of characterizing its interactions with both the host cell–surface receptor ACE2 and the drug candidates capable of disrupting this interaction. In this work, we evaluate the utility of native MS complemented with the experimental methods using gas-phase chemistry (limited charge reduction) to obtain meaningful information on the association of the S1 domain of the S-protein with the ACE2 ectodomain, and the influence of a small synthetic heparinoid on this interaction. Native MS reveals the presence of several different S1 oligomers in solution and allows the stoichiometry of the most prominent S1/ACE2 complexes to be determined. This enables meaningful interpretation of the changes in native MS that are observed upon addition of a small synthetic heparinoid (the pentasaccharide fondaparinux) to the S1/ACE2 solution, confirming that the small polyanion destabilizes the protein/receptor binding.

show abstract

Section: Discussionmentioning

confidence: 99%

The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor

2021

View full text Add to dashboard Cite

show abstract

“…Either a variant virus evolved in bats and/or the intermediate host before transmission to humans or the virus transmitted to humans as a bat or intermediate host virus and evolved in humans. The SARS-CoV-2 genome showed 88% homology with Chinese bat coronaviruses, 79% homology with SARS-CoV and 50% homology with MERS-CoV, which suggests the former 2,3 . Natural SARS-CoV-2 infections have been reported in cats, dogs, mink, tigers, and lions and experimental infections in mice, hamsters, cats, ferrets, non-human primates, and tree shrews.…”

Section: Introductionmentioning

confidence: 96%

COVID-19 in animals: contact with humans and potential transmissions

Selleck¹

2021

Microbiol. Aust.

View full text Add to dashboard Cite

In December 2019, cases of atypical pneumonia were diagnosed in hospital patients in Wuhan, Hubei province, China. The disease was characterised by a respiratory disorder of variable severity ranging from mild upper respiratory tract illness to acute respiratory distress syndrome, severe interstitial pneumonia and death. The source of the virus is yet to be confirmed but wild animals sold at wholesale seafood and exotic animal markets of Wuhan were implicated. The virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease designated as Coronavirus disease-19 . As of the 13 January 2021, the WHO had reported 90 335 008 cases and 1 954 336 deaths in 216 countries. The isolation of related coronaviruses from bats suggests that they may be a potential host species. This paper is a review of the current literature on SARS-CoV-2 infections of animals and the animal challenge models for the in-vivo evaluation of vaccines and therapeutics.

show abstract

“…Some unusual features of the SARS-CoV-2 genome sequence suggest that they may have resulted from genetic engineering, 15 , 16 an approach widely used in some virology labs. 17 Alternatively, adaptation to humans might result from undirected laboratory selection during serial passage in cell cultures or laboratory animals, 5 , 18 , 19 including humanised mice. 20 Mice genetically modified to display the human receptor for entry of SARS-CoV-2 (ACE2) were used in research projects funded before the pandemic, to test the infectivity of different virus strains.…”

mentioning

confidence: 99%

“…Overwhelming evidence for either a zoonotic or research-related origin is lacking: the jury is still out. On the basis of the current scientific literature, complemented by our own analyses of coronavirus genomes and proteins, 5 , 15 , 16 , 18 , 29 , 30 we hold that there is currently no compelling evidence to choose between a natural origin (ie, a virus that has evolved and been transmitted to humans solely via contact with wild or farmed animals) and a research-related origin (which might have occurred at sampling sites, during transportation or within the laboratory, and might have involved natural, selected, or engineered viruses).…”

mentioning

confidence: 99%